What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – October 2026

October was a busy month for the pulmonary hypertension community. The Alliance for Pulmonary Hypertension added five new PEP Talks and, together with the European Pulmonary Fibrosis Federation (EU-PFF), held a webinar on pulmonary hypertension associated with interstitial lung disease. On the treatment front Gossamer Bio has submitted a New Drug Application (NDA) for seralutinib […]

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – October 2026 Read Post »

Extension Studies in Treprostinil Palmitil Inhalation Powder (TPIP) Show Promise in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), American Journal of Managed Care, October 20, 2026

At the annual meeting of the American College of Chest Physicians, October 18-21. 2026, Insmed presented new data on treprostinil palmitil inhalation powder. This is an investigational inhaled prostacyclin-pathway drug that is released slowly in the lungs, so a single daily dose works for 24 hours. Current inhaled treprostinil needs four sessions a day. In

Extension Studies in Treprostinil Palmitil Inhalation Powder (TPIP) Show Promise in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), American Journal of Managed Care, October 20, 2026 Read Post »

Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026

Quince Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, has announced that it has changed its name to IRulya Therapeutics Inc. IRulya will be focused on advancing LAM-001, an investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases. LAM-001 is a

Update on investigational formulation of inhaled rapamycin (mTOR inhibitor) for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome after lung transplant, October 9, 2026 Read Post »

Every Breath Counts: The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), European Medical Journal, October 20, 2026

This article contains an abstract and full transcript of a symposium which took place on 6th September 2026, as part of the European Respiratory Society (ERS) Congress held in Barcelona, Spain, sponsored by INSMED. The Chairperson was Professor Jean-Luc Vachiery and the speakers were Professors Irene Lang (Medical University, Vienna, Austria) Hossein Ardeschir Ghofrani (Giessen

Every Breath Counts: The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), European Medical Journal, October 20, 2026 Read Post »

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026

The pipeline VLR199 (the lead candidate): works in the same way as sotatercept (Winrevair), by trapping proteins of the activin family that drive the abnormal growth of cells in the lung vessels. The aim is to improve on aspects of sotatercept that may not be “fully optimised”. First clinical results showing whether it works are

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026 Read Post »

Join the European Pulmonary Fibrosis Federation (EU-PFF) and the Alliance for Pulmonary Hypertension for a webinar on pulmonary hypertension associated with interstitial lung disease (PH-ILD) on October 21, 2026, at 18:00.

On 21 October at 18:00 CET, join the European Pulmonary Fibrosis Federation (EU-PFF) and the Alliance for Pulmonary Hypertension for a webinar titled “Together for PH-ILD: Strengthening Awareness, Care, and Patient Support”. The webinar will bring together clinicians and patient advocates to discuss how cross-collaboration can improve awareness, care and support for people living with

Join the European Pulmonary Fibrosis Federation (EU-PFF) and the Alliance for Pulmonary Hypertension for a webinar on pulmonary hypertension associated with interstitial lung disease (PH-ILD) on October 21, 2026, at 18:00. Read Post »

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – September 2026

September was a busy month in the pulmonary hypertension world, with the European Society of Cardiology (ESC) and European Respiratory Society Congresses (ERS) bringing a wave of new research. The most important news is the update of the ERS Clinical Practice Guidelines for the treatment of pulmonary arterial hypertension (PAH), presented in Barcelona. AfPH Vice

What’s new on the Pulmonary Hypertension Knowledge Sharing Platform – September 2026 Read Post »

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension

Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and Chair of the Dutch pulmonary hypertension foundation, attended both the European Society of Cardiology and the European Respiratory Society (ERS) Annual Congresses 2026 taking place respectively in Munich, Germany (August 28-30), and Barcelona, Spain (September 5-9). Based on the sessions she followed, she has

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension Read Post »

Pulmovant announces positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

The findings of the Pulmovant Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD, Group 3 of the World Health Organisation, WHO, pulmonary hypertension classification) were presented on September 8, 2026, at the European Respiratory Society (ERS) International Congress 2026 by Marc Humbert, MD, PhD, Professor of Respiratory Medicine

Pulmovant announces positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) Read Post »

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1

Following the 7th World Symposium on Pulmonary Hypertension, a review published in the European Respiratory Journal summarises the current understanding of Pulmonary hypertension associated with interstitial lung disease (PH-ILD). It covers the condition’s clinical features, underlying biology, diagnosis, prognosis and treatment, while flagging diagnostic challenges — from overlapping symptoms to the lack of specific biomarkers

Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review, European Respiratory Journal, Vol 68 Issue 1 Read Post »

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026

For 30 years, pulmonary arterial hypertension (World Health Organisation, WHO, Group 1 pulmonary hypertension) treatment relied on three vasodilator-based pathways: endothelin receptor antagonists (bosentan, ambrisentan, macitentan), the nitric oxide/cGMP pathway (sildenafil, tadalafil, riociguat), and prostacyclin pathway agents (treprostinil, epoprostenol, selexipag, etc.). These improve symptoms and slow progression but don’t modify the underlying vascular disease, and

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026 Read Post »

How Do Sleep Difficulties Interact With Anxiety, Depression and Health-Related Quality of Life in Pulmonary Hypertension? – Clinical Respiratory Journal, August 2026

A cross-sectional study surveyed 111 adults with pulmonary hypertension (see table below for different forms), predominantly UK-based, White, and female, to examine sleep problems and their psychological/quality-of-life impact. The design and procedure of the study were developed in association with the UK Pulmonary Hypertension Association, PHA UK, and medical experts in pulmonary hypertension. Key findings:

How Do Sleep Difficulties Interact With Anxiety, Depression and Health-Related Quality of Life in Pulmonary Hypertension? – Clinical Respiratory Journal, August 2026 Read Post »

Caring for the whole person, a conversation with Susanne McDevitt, critical care nurse practitioner with the Pulmonary Hypertension (PH) Program, University of Michigan, Ann Arbor

Beyond hemodynamics and treatment targets, there are conversations with patients that rarely make it into clinical guidelines — yet they’re often the ones that matter most. That’s the message from Susanne McDevitt, DNP, a critical care nurse practitioner with the Pulmonary Hypertension (PH) Program at Michigan Medicine, University of Michigan, Ann Arbor. In a conversation

Caring for the whole person, a conversation with Susanne McDevitt, critical care nurse practitioner with the Pulmonary Hypertension (PH) Program, University of Michigan, Ann Arbor Read Post »

Cereno Scientific announces partnership with PHA Europe on patient-centered pulmonary hypertension drug design, May 11, 2026

Swedish biotech Cereno Scientific has announced a collaboration with PHA Europe & Global, aimed at integrating the patient perspective more systematically into clinical trial design and execution. Cereno is developing two experimental medications that could expand choices in this space: CS1 for pulmonary arterial hypertension (PAH) and CS014 for pulmonary hypertension associated with lung disease (PH-ILD). The

Cereno Scientific announces partnership with PHA Europe on patient-centered pulmonary hypertension drug design, May 11, 2026 Read Post »

United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US)

United Therapeutics announced positive data from the TETON-1 phase 3 pivotal study of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF), and of the ADVANCE OUTCOMES and ARTISAN studies on pulmonary arterial hypertension at the American Thoracic Society’s International Conference on May 15-20, in Orlando (see also our previous article at this link) The following posters

United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US) Read Post »

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026

Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026 Read Post »

AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension with Interstitial Lung Disease (ILD-PH), April 9, 2026

AllRock Bio has dosed the first patients in its Phase 2a ROCSTAR trial, evaluating ROC-101 — a potential first-in-class oral pan-rho-associated protein kinase (ROCK) inhibitor — in patients with pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The open-label, multicenter, exploratory study will evaluate the safety, tolerability, and efficacy of ROC-101 in both

AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension with Interstitial Lung Disease (ILD-PH), April 9, 2026 Read Post »

Promising results for nebulised treprostinil (Tyvaso) in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), WHO Group 3

United Therapeutics reported positive results from TETON-1, its second Phase III trial testing nebulised Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF). The trial, involving 598 patients over 52 weeks, showed that nebulised Tyvaso was superior to placebo in improving forced vital capacity (FVC) by 130.1 mL, and also achieved statistical significance in reducing the risk

Promising results for nebulised treprostinil (Tyvaso) in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), WHO Group 3 Read Post »

Cereno Scientific receives approval to initiate FDA-aligned Phase I pharmacokinetic study of CS014 supporting Phase II development in pulmonary hypertension associated with interstitial lung diseases (PH-ILD)

Swedish biotech Cereno Scientific has received approval from the Swedish Medical Products Agency to begin a Phase I study of its experimental drug CS014, a new HDAC inhibitor being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study, designed in line with FDA guidance, will compare CS014’s pharmacokinetics to valproic acid (VPA),

Cereno Scientific receives approval to initiate FDA-aligned Phase I pharmacokinetic study of CS014 supporting Phase II development in pulmonary hypertension associated with interstitial lung diseases (PH-ILD) Read Post »

TRANSLATE »
Scroll to Top